Kymera Therapeutics has a pipeline of preclinical drug candidates that use an experimental approach to get rid of disease-causing proteins and it’s now looking to tap the public markets to finance tests of the technology in humans.
In paperwork submitted to the Securities and Exchange Commission on Friday, Kymera set a $100 million goal for its IPO. The filing comes three weeks after the Cambridge, MA-based biotech inked a multi-year, multi-product R&D partnership with Sanofi (NYSE: SNY) that paid $150 million up front.
Kymera is developing drugs that harness protein degradation, a cell’s built-in process for recycling or disposing of… Read more »
UNDERWRITERS AND PARTNERS
